Target intelligence / Profile preview

Cancer Antigen 1 (CAGE1)

Target: CAGE1
Molecular classification: Cancer/testis antigen, Tumor-associated antigen

Overview

CAGE1 is a cancer/testis antigen, normally expressed in testis but aberrantly expressed in various tumors. Its restricted expression profile makes it a potential target for cancer immunotherapy. Promoter methylation influences its expression, suggesting a role in tumor development. It has been associated with supraglottic neoplasm and intraocular retinoblastoma.

Other names: Cancer-associated gene protein 1

Mechanism of action

Not applicable; target for immunotherapy (vaccines, antibodies)

Biological functions

Immune responseOther

Disease associations

Cancer

Safety considerations

Potential for off-target effects due to expression in testisImmunogenicity

Biomarkers

CAGE1 expression in tumor tissue

Beyond the preview

Go deeper on Cancer Antigen 1 (CAGE1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer Antigen 1 (CAGE1).

Explore the full profile